Breaking News

DSM, Chemtrix In Continuous Flow Chemistry Pact

February 20, 2013

Aims to provide new processes for API development and manufacture

DSM Pharmaceutical Products and Chemtrix BV have signed a collaboration agreement in the field of continuous flow chemistry to provide equipment, development and manufacturing services to the pharmaceutical industry. The agreement combines the chemistry expertise of both companies and aims to provide new technologies and processes for the development and manufacture of APIs to increase sustainability, reduce energy consumption and provide benefits for cost-of-goods.
Chemtrix will contribute its ready-to-use lab and kilo-scale micro reactors, as well as reactor and process design for industrial reactors, and DSM will employ its expertise in drug synthesis route development, scale-up and implementation of continuous flow processes for manufacturing. Initially the collaboration will offer an Industrial Flow Process Development package to clients to provide custom, scalable flow chemistry solutions, which covers all phases of process design, from scanning chemistries, chemistry development, route scouting, equipment design and scale-up.
Alexander Wessels, president and chief executive officer of DSM Pharmaceutical Products, said, "Working with Chemtrix underlines the further advancement of DSM's stated strategy toward strategic partnerships to excel in providing new customer solutions. DSM is a global leader in cGMP continuous flow chemistry manufacturing, with a commitment to the future of pharmaceutical manufacturing in a sustainable manner." 
Hugo Delissen, chief executive officer of Chemtrix BV, said, "Together with DSM we are the most complete flow chemistry partner for pharmaceutical and fine chemical companies. Delivering a complete package of equipment and services based on our joint knowledge ranging from lab (milligrams) to production (ton) scale, ensures the delivery of the best possible solutions for our joint customers."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016